Wang, HuaChen, XChen, ZhixianLu, WPoerschke, GabrieleEves, KarenGress, JacquelineKuter, Barbara2009-05-272009-05-272004-12-27Wang H, Chen X, Chen Z, Lu W, Poerschke G, Eves K, Gress J, Kuter B. Field performance of VAQTA (inactivated, purified hepatitis a vaccine) in Chinese children in Jiangsu. The Southeast Asian Journal of Tropical Medicine and Public Health. 2004 Dec; 35(4): 949-53http://imsear.searo.who.int/handle/123456789/34236The Southeast Asian Journal of Tropical Medicine and Public Health.In Jiangsu, 30% of children between the ages of 5 and 8 years test seropositive for hepatitis A. The safety, tolerability, and immunogenicity of a 2-dose regimen (0, 6 months) of VAQTA (0.5 ml of 25U) administered IM in 50 healthy children aged 5 to 8 years without prior serological screening was evaluated. Blood samples were collected prior to the first dose and after each additional dose of VAQTA to determine the initial anti-HAV serostatus and response rates to the vaccine. Twelve children (24%) were initially seropositive and 38 (76%) were initially seronegative. Four weeks after the primary dose of VAQTA, 34 of the 38 subjects (89.5%, 95% CI 75 to 97) were anti-HAV seropositive. The geometric mean titer was 33.1 mIU/ml (95% CI 22.4 to 49.0). After the booster dose at 6 months, all the subjects were seropositive (37/37), giving a seroconversion of 100% (95% CI: 90, 100). The geometric mean titer was 7585.8 mIU/ml (95% CI: 5623.4 to 10,471.3). Adverse experiences were generally mild and transient. Results of this study are consistent with results from a previous double-blind randomized trial of this vaccine and confirm that VAQTA is highly immunogenic, and generally well-tolerated.engChildChild, PreschoolChinaFemaleHepatitis A --bloodHepatitis A Vaccines --adverse effectsHumansMaleJournal Article